Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
YMAB.US
id: 549, Created by Stan Vick, Scout
Y-mAbs Therapeutics Negligence Case
What do I get by joining?
- You will get case updates and receive a payout in case of success
- If you would like to actively participate, you will be connected to the attorney
- No, you do not pay anything out of your pocket neither to us nor to attorney
S.D. New York
Court23-CV-00431
Case numberOn October 28, 2022, the FDA’s Oncologic Drugs Advisory Committee voted unanimously against approving the Y-mAbs’s (NASDAQ: YMAB) marketing application for omburtamab.
On this news, Y-mAbs’s stock price dropped over 59%, seriously damaging investors.
Earlier on October 26, 2022, the FDA released briefing documents expressing concerns that the Biologics License Application for the Company’s product candidate does not provide sufficient evidence of efficacy. The FDA cited the fact that the Company submitted data:
- from just a single center, single-arm trial;
- that additional analyses conducted by the FDA to examine bias and results found that differences in survival cannot be reliably attributed to omburtamab;
- and that the application does not include reliable response rate data to provide supportive evidence of the treatment effect of omburtamab.
On this news, YMAB's price fell over 27%.
Taking the nature of the issues into account, Investors have all reasons to suspect that the Company and its Leaders did not conduct the due performance of their work, which led to rejected application with the FDA.
Alleged Offence
Mismanagement,
Misleading Statements,
Malpractice,
Negligence,
Breach of Fiduciary duty,
Omissions
Suspected Party
Directors,
Management,
Government Authority,
Service Provider,
Research Entity
Security Type
Stocks
Trade Direction
Long
Shock Event Date
28 October 2022
Lead Plaintiff Deadline
21 March 2023